Guide · Evidence

Do menopause supplements work? What the trials actually show

What placebo-controlled trials show for black cohosh, soy, ERr 731, pollen extract, S-equol and more, who funded them, and what The Menopause Society recommends.

Last updated · By the Solynes editorial team · Methodology

Short answer: A few ingredients show modest effects in some trials, but the best independent trials mostly find no clear benefit over placebo, and The Menopause Society's 2023 position statement recommends no dietary supplement for hot flashes. Soy isoflavones have the most consistent data (about 20% fewer hot flashes than placebo in one meta-analysis). Most branded ingredients rest on small trials paid for by the companies that sell them.

The evidence, ingredient by ingredient

Grades: A strong · B moderate · C limited · D none or negative (see how we grade).

Ingredients studied for hot flashes and other menopause symptoms.
IngredientGradeTrialsWhat reviews concludeMenopause Society 2023
Soy isoflavones & genisteinB-dozens (Cochrane 2013 phytoestrogens: 43 RCTs; Taku 2012: 17 in MA)Taku 2012: -20.6% frequency, -26.2% severity vs placebo; Franco JAMA 2016: -0.79 hot flashes/day; Cochrane 2013: no conclusive evidence, possible benefit at >30 mg genistein; NCCIH: effect may be small.Not recommended (Level II) – mixed evidence.
Red cloverC+~9 placebo RCTs (Jiang 2026 GRADE MA)Cochrane 2013: Promensil no significant effect; Gartoulla 2014: benefit at 3–4 mo, not 12 mo; Kanadys 2021: -1.73/day; Jiang 2026: SMD -0.45. Geller 2009 12-mo RCT null.Not specifically named (supplements not recommended).
Black cohoshC≥16 RCTs in Cochrane 2012; 22 articles in Sadahiro 2023 MACochrane 2012 (16 RCTs, 2,027 women): no difference vs placebo for hot-flush frequency. Sadahiro 2023 MA: small-moderate benefit (g 0.32 hot flashes). Manufacturer-affiliated iCR MA (2021): positive, dose-dependent. Large independent US trials (HALT 2006, Geller 2009, Pockaj 2006) null. IMS 2026 review: moderate certainty for benefit.Not recommended (Level I) – 'insufficient evidence to support use for VMS'.
ERr 731 rhapontic rhubarbC3 placebo RCTs by one research group (Heger 2006 n=109; Kaszkin-Bettag 2009 n=112; + earlier anxiety analysis) + Indian open-labelDubey 2024 MA (4 studies, 390 women; industry-affiliated authors): MRS -15 points vs control.Not recommended (Level II) – placebo-arm retention only 12.7% in key RCT; open-label study.
Flower pollen extractC2 small placebo RCTs (Winther 2005 n=64; Bounous 2024 n=39 breast-cancer survivors) + observationalAcquarulo 2024 MA (1 RCT + 4 observational, n=420): big before/after changes, but pooled controlled data NOT significant – possibly placebo.Not recommended (Level III).
S-equolC~5–6 RCTs (Daily 2019 MA: 6 studies, 779 women)Daily 2019 MA: benefit on hot-flash scores, 3/5 trials positive, 2 null; most trials <50/group.Not recommended (Level II) – mixed evidence.
EstroG-100C3 placebo RCTs (Chang 2012 n=64; Farzaneh 2024 n=120/70 analyzed; Snigdha 2025 n=80 combo with GABA)No independent meta-analysis found.Not specifically assessed (falls under 'supplements/herbal remedies – not recommended').
Ammonium succinate (Amberen)C2 identical placebo RCTs (pooled n=227) + 1 open-label combo study (n=106)Only manufacturer-linked pooled analysis (2019).Not recommended (Level II) – limited, manufacturer-sponsored.
Pycnogenol (pine bark)C3 placebo/controlled RCTs (n=170, ~200, 38) Cochrane 2020 (pine bark, chronic disorders) did not include menopause and found low-quality evidence overall.Not assessed.
FenugreekC≥3 placebo RCTs (n=115, 88, 138+ with shatavari)No MA located.Not assessed.
SageC~4 placebo RCTs (310 women, Moradi 2023) + open-labelMoradi 2023: frequency effect not significant overall.Not assessed.
Hops (8-PN)C-3–4 small RCTs (n=36–120) + soy-hop comboNo MA located.Not assessed.
Evening primrose oilD~6 RCTs (Larki 2025 MA, 450 women)Thevi 2024 & Larki 2025: no significant reduction in frequency; possible small severity effect.Not recommended (Level II).
Omega-3 (fish oil)D2 key RCTs (Lucas 2009 n=120; Cohen 2014 n=355)Iqbal 2023 SR: no substantial evidence for VMS, sleep or depression.Not recommended (Level III) – mixed.
MagnesiumD1 large RCT (Park 2015, n=289)Null for hot flashes.Not assessed.

Why placebo matters so much

Hot flashes improve a lot on placebo. In an NIH-funded 12-month trial (Geller 2009), hot flashes fell 63% on placebo, 34% on black cohosh and 57% on red clover, versus 94% on hormone therapy. Neither botanical beat placebo. The NIH-funded HALT study (Newton 2006) found no herbal arm differed from placebo by even one hot flash a day, while hormone therapy reduced about four a day.

That is why before-and-after results (“73% fewer hot flashes”) say little on their own. For pollen extract, a 2024 meta-analysis (Acquarulo 2024) found large before-and-after changes, but when only controlled studies were pooled, the effect was not statistically significant.

Who pays for the research

By our reading of the funding statements in our 79-entry study library, 19 are linked to a manufacturer or ingredient supplier and 34 are independent or academic; 25 do not state funding in the abstract. Examples: the main S-equol trials were funded by Otsuka and Pharmavite; the EstroG-100 + GABA trial behind OLLY Mellow Menopause was run by OLLY employees (Snigdha 2025); the Amberen trials are manufacturer-linked (Radzinsky 2019).

Where the evidence is most promising

Where it isn't

What does have evidence

The Menopause Society's 2023 nonhormone statement lists CBT, clinical hypnosis, SSRIs/SNRIs, gabapentin, fezolinetant (Level I), oxybutynin (I–II), weight loss, stellate ganglion block (II–III). Hormone therapy is also an option for many women. These are prescribed or delivered by clinicians, so the most useful next step for bothersome symptoms is a conversation with one. Read the statement (PDF).

If you still want to try a supplement

See all 27 products ranked

FAQ

Is there any menopause supplement proven to work?

No supplement has strong (grade A) evidence for hot flashes, and The Menopause Society (2023) recommends none. Soy isoflavones show a modest average effect in meta-analyses (grade B-).

What works better than supplements for hot flashes?

The Menopause Society lists hormone therapy and non-hormonal options with evidence: CBT, clinical hypnosis, SSRIs/SNRIs, gabapentin, fezolinetant (Level I), oxybutynin (I–II), weight loss, stellate ganglion block (II–III). Ask a clinician which fits you.

More guides

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Solynes does not sell supplements; descriptions summarize published research and are not medical advice.